



7TH ANNUAL MEETING
Vilnius • 2023

7th Meeting of the European Hereditary Tumour Group (EHTG)

Friday, Sept 29th – Sunday, Oct 1st 2023

Vilnius, Lithuania

Final Program



Invitation

7th Meeting - Vilnius, Lithuania

Dear Members, Friends, Affiliates and Sponsors,

We are delighted to invite you to the 7th annual EHTG meeting in beautiful Vilnius, Sept. 29 to Oct. 1 2023. Our lively program includes selected hot and controversial topics, debates, new interactive formats and our workshop day with in-depth scientific discussions. Join us in person or online during the hybrid event!

Days 1 (Friday) and 3 (Sunday) will follow the plenary format without parallel sessions. Day 2 (Saturday) is our dedicated working group (WG) day, with three parallel groups. The submitted abstracts were allocated to be presented in the different WGs and the highest rated abstracts will also be presented in a separate "best abstracts" session (day 1)

Additionally, our meeting dates are back-to-back with the European Society of Coloproctology's annual conference on Sept 27-29; we envisage that bilateral synergistic effects will result from this collaborative meeting. On Thursday, Sept. 28, we will host the ESCP-EHTG joint symposium at the ESCP venue. On Saturday, an additional EHTG-ESCP workshop is scheduled for clinicians interested in surgical management of hereditary predisposition syndromes.

After last year's successful launch, our 7th meeting provides an open platform for patient societies and networking. Continuing our international collaboration in this field, we welcome and encourage patients and patient societies to join us in person or virtually in Vilnius.



Vacation in beautiful Vilnius? Why not spend a few days before or after the meeting? Our venue, The Panorama Hotel, is located in Vilnius' old town, only 1.5km from the Gate of Dawn. The hotel's top-floor lounge gives guests spectacular panoramic city views. The historic Gediminas Tower and Town Hall Square can be reached within a 15-minute walk. Or head out further afield with the bus and train stations only a 3-minute walk from the Hotel.

Visit www.ehtg.org for more information and contact gs007@ehtg.org for all organisational queries. If you have any suggestions, please get in touch with any of the board members.

We are genuinely excited to see you in Vilnius!

Sincerely, your EHTG Board Members



7TH ANNUAL MEETING
Vilnius • 2023



Content

Invitation	2-3
Organisation	5
Overview day 1	6
Overview day 2	7
Overview day 3	8
Day 1 – Friday, September 29th	
(wh)y-EHTG Session	10
Opening Remarks / Plenary Session 1	10
Big Debate.	11
Panel discussion	11
Best of Abstracts	12-13
Welcome Reception.	13
EHTG Nurses Meeting.	14
y-EHTG Social Networking	13/14
Day 2 – Saturday, September 30th	
Open PLSD Meeting.	15
Working Group 1.	16-17
Working Group 2.	18-19
Working Group 3.	19-20
Working Group 4.	20-21
Working Group 5.	22
Working Group 6.	23
Working Group 7.	24-25
Working Group 8.	26
Working Group 9.	27
CMMRD Session	28
EHTG-ESCP international Surgery Day “iSTOIC”.	30-31
Conference Dinner	29
Day 3 – Sunday, October 1st	
EHTG Business Meeting	32
WG Reporting Back Session and Collaborative Studies ..	32
Hot Topics.	32
Networking with patients and their organizations	32
Pathology and clinical data in childhood	32
Late Breaking Abstracts	33
Newly emerging technologies	33
Farewell.	33
Faculty	34-41
Sponsors	42
Imprint	42

Organisation

Board Members: Aysel Ahadova (Germany)
 Peter Bauerfeind (Switzerland)
 John Burn (United Kingdom)
 Mev Dominguez Valentin (Norway)
 Fiona Laloo (United Kingdom)
 Gabriela Moslein (Germany)
 Pål Møller (Norway)
 Julian Sampson (United Kingdom)
 Toni Seppala (Finland)
 Rolf Sijmons (The Netherlands)
 Sanne ten Broeke (The Netherlands)

Program Committee: Mev Dominguez Valentin (Norway)
 Aysel Ahadova (Germany)
 Elizabeth Half (Israel)
 Kelly Kohut (UK)
 Neil Ryan (UK)
 Sanne ten Broeke (The Netherlands)
 Laura Thomas (UK)
 Ingrid Winship (Australia)

Secretariat: Gabriele Sponholz
gs007@ehtg.org
 +49-160-8459502
 D-65207 Wiesbaden (Germany)

Location: Panorama Hotel, Vilnius, Lithuania
<https://panoramahotel.lt/reservation@panoramahotel.lt>
 Only direct booking

Registration: Only online via www.ehtg.org

Registration Fee: See online via www.ehtg.org

Certification: We have applied for certification by EACCME and expect the same certification as last year (6/8/5)

Meeting Overview

Day 1 – Friday, September 29th

Time	Event
08:00 - 09:00	Registration
09:00 - 11:00	(wh)y-EHTG Session
11:00 - 11:30	Coffee Break
11:30 - 13:30	Plenary Session 1
13:30 - 14:30	Lunch
14:30 - 15:15	Big Debate
15:15 - 16:15	Panel discussion Gynaecological Surveillance
16:15 - 16:45	Coffee Break
16:45 - 17:45	Best of Abstracts
17:45 - 18:15	Welcome Reception
17:45 - 18:15	EHTG Nurses Meeting
20:00 +	y-EHTG Social Networking

We look forward to your personal attendance, but also offer the meeting with all sessions live online.

Meeting Overview

Day 2 – Saturday, September 30th

Time	Event
08:00 - 09:00	Open PLSD Meeting
09:00 - 11:00	Parallel Working Groups 1 - 3 EHTG-ESCP international Surgery Day "iSTOIC"*
11:00 - 11:30	Coffee Break
11:30 - 13:30	Parallel Working Groups 4 - 6 EHTG-ESCP international Surgery Day "iSTOIC"*
13:30 - 14:30	Lunch
14:30 - 16:30	Parallel Working Groups 7 - 9 EHTG-ESCP international Surgery Day "iSTOIC"*
	* International Surgical Group of Those Operating on Inherited colorectal Cancer
16:30 - 17:00	Coffee Break
17:00 - 18:30	CMMRD Session
19:30 +	Conference Dinner

We look forward to your personal attendance, but also offer the meeting with all sessions live online.





Meeting Overview

Day 3 – Sunday, October 1st

Time	Event
08:00 - 09:00	EHTG Business Meeting
09:00 - 10:00	WG Reporting Back Session and Collaborative Studies
10:00 - 10:30	Coffee Break
10:30 - 11:30	Hot Topics
11:30 - 12:30	Networking with patients representatives and organizations
12:30 - 13:00	Pathology and clinical data in childhood
13:00- 13:30	Lunch
13:30 - 14:00	Late Breaking Abstracts
14:00 - 14:45	Newly emerging technologies
14:45 - 15:00	Farewell

We look forward to your personal attendance, but also offer the meeting with all sessions live online.

Notes



7TH ANNUAL MEETING
Vilnius • 2023

Scientific Program

Day 1 – Friday, September 29th

Room
Humanitas

08:00-09:00

Registration

09:00-11:00

(wh)y-EHTG Session

Chairs: *Sanne Bajwa-ten Broeke (Netherlands)*
Demetra Georgiou (UK)
Aysel Ahadova (Germany)

Top abstract 1

Co-design of the Lynch Choices patient resource including cultural translation to improve equity, diversity and inclusion
Kelly Kohut (UK)

8'+2'

Top abstract 2

The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation
Lena Bohaumilitzky (Germany)

8'+2'

Top abstract 3

Co-evolution of mismatch repair loss and the immune response in Lynch syndrome
Ottillie Swinyard (UK)

8'+2'

09:30-10:00

Y-EHTG Dragons Den for new proposals

10:00-11:00

Y-EHTG show & tell

11:00-11:30

Coffee Break

11:30-13:30

Opening remarks

Gabriela Moeslein (Germany)

2'

Plenary Session 1

Chairs: *Ann-Sofie Backman (Sweden)*
Matthias Kloor (Germany)
Zohar Levi (Israel)

Clinical Translation of Cancer Immunoprevention

Shizuko Sei (USA)

15'+5'

Evolving therapy of MMR-deficient CRC

Frank A. Sinicrope (USA)

15'+5'

EHTG initiative: harmonization of global Lynch syndrome guidelines

Giulia Cavestro (Italy)

15'+5'

Scientific Program

Day 1 – Friday, September 29th

Room
Humanitas

15'+5'

New updated guidelines for FAP

Gloria Zaffaroni (Italy)

15'+5'

Prenatal and Preimplantation Genetic Diagnosis

Yael Goldberg (Israel)

15'+5'

Guidelines for transgender care in Lynch Syndrome / Transgender challenges in healthcare

Rachel Hodan (USA)
Esther van Enckevort (The Netherlands)

13:30-14:30

Lunch

14:30-15:15

Big Debate – Urological Surveillance

Chairs: *Elizabeth Half (Israel)*
Richard Gallon (UK)
Tanya Bisseling (The Netherlands)

15'

Urological surveillance in Lynch syndrome an opportunity for early detection? Possible and necessary/not an option and is unnecessary

Marco Moschini (Italy)
Ulla Nordstroem (Denmark)

15'

15:15-16:15

**Panel discussion
Gynaecological Surveillance**

Is there a role for gynaecological surveillance in Lynch syndrome/HBOCS?

Chairs: *Neil Ryan (UK)*
Emma Crosbie (UK)
Anja Wagner (The Netherlands)

7' + 3'

Ovarian cancer prevention in high-risk groups

Robert Fruscio (Italy)

7' + 3'

Universal germline testing and/or dMMR tumor screening among all endometrial cancer patients

Heather Hampel (USA)

7' + 3'

Gynaecological surveillance in high-risk groups in The Netherlands

Ellis Eikenboom (The Netherlands)

30'

Panel Discussion

Scientific Program

Day 1 – Friday, September 29th

Room
Humanitas

16:15-16:45 Coffee Break

16:45-17:45

Best of Abstracts

Chairs: *Gabriel Capella (Spain)*
Jane Hübertz Frederiksen (Denmark)
Lena Bohaumilitzky (Germany)

5'

Cancer in patients with Familial adenomatous polyposis - a nationwide Danish cohort study with matched controls.

Anne Marie Jelsig (Denmark)

5'

Whole genome sequencing findings in families tested negative based on family history -

Mev Dominguez (Norway)

5'

Experiences from direct provider-mediated cascade-testing in Lynch syndrome families – the Danish model.

Lars Lindberg (Denmark)

5'

Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort.

Anja Wagner (The Netherlands)

5'

Comprehensive molecular profiling of patient-derived tumor organoids uncovers in vitro drug sensitivities of sporadic and hereditary colorectal cancers.

Erdogan Pekcan Erkan (Finland)

5'

Guidelines in „plain language“ for patients affected by Lynch syndrome. Abstract 50

Katlijn Sanctorum (Belgium)

5'

Germline variants in PARP1 as potential cause of colonic polyposis in adults. Abstract 20

Laura Valle (Spain)

5'

Detection of microsatellite instability using plasma-derived extracellular vesicle DNA – a new perspective for tumor surveillance in Lynch syndrome?

Lena Bohaumilitzky (Germany)

Scientific Program

Day 1 – Friday, September 29th

Room
Humanitas

5'

The optimal endoscopic surveillance in hereditary diffuse type gastric cancer; random or targeted biopsy taking?

Tanya Bisseling (The Netherlands)

5'

Impact of Pathogenetic MMR Genotypes on Systemic Metabolic Signatures.

Tiina Jokela (Finland)

5'

An Exploration of the Somatic and Germline Mutational Profiles of Early-Onset Colorectal Cancer Based on Two UK Patient Cohorts.

Penelope Edwards (UK)

5'

Colibactin mutational signatures in NTHL1 Tumor Syndrome, MUTYH Associated Polyposis and unexplained polyposis patients.

Diantha Terlouw (The Netherlands)

17:45-18:15

Welcome Reception

20:00 +

y-EHTG Social Networking



Scientific Program

Day 1 – Friday, September 29th

Room
Humanitas

18:30-20:00 EHTG Nurses Meeting

- 18:30-18:35 **Welcome and introduction**
Laura Monje-Garcia (UK)
Mechelle Loughrey (Ireland)
- 18:35-18:45 **Summary of role and objectives of the EHTG**
Committee Member
- 18:45-19:15 **Snapshot of current hereditary cancer nursing services**
Mechelle Loughrey (Ireland)
Laura Monje-Garcia (UK)
Celia Diez de los Rios (Spain)
- 19:15-19:25 **Opportunity for attendees to discuss their service**
Open
- 19:25-19:35 **Question time**
Open
- 19:35-19:45 **Service improvement +/- site visits, Research collaboration opportunities**
Laura Monje-Garcia (UK)
Mechelle Loughrey (Ireland)
- 19:45-20:00 **Brainstorming session regarding future meetings board membership etc.**
Open

20:00 + y-EHTG Social Networking

Scientific Program

Day 2 – Saturday, September 30th

08:00-09:00 Open PLSD Meeting

Room
Humanitas

- 8:00-8:10 **Overview of the PLSD**
Mev Dominguez-Valentin (Norway)
- 8:10-08:25 **The four Lynch syndromes - where are we?**
- Time since last colonoscopy as surrogate for RTC?
- Polyps and CRC incidences?
Pål Møller (Norway)
- 08:25-08:30 **Studies on gynaecological surveillance?**
Neil Ryan (UK)
- 08:30-08:35 **PRS and panel testing?**
Mev Dominguez-Valentin (Norway)
- 08:35-08:40 **Call for new data: PLSDv6**
Mev Dominguez-Valentin
- Including polyp data?
- Including immunotherapy?
- Including more genes?
Mev Dominguez-Valentin (Norway)
- 08:40-08:55 **General discussion**
All



European Hereditary
Tumour Group

PLSD
The Prospective Lynch Syndrome Database

Scientific Program

Day 2 – Saturday, September 30th

09:00-11:00 Joint ESCP-EHTG Hereditary Surgery Symposium
See page 30-31 for details

09:00-11:00 Parallel Working Groups 1-3

09:00-11:00 **Group 1 – Gastroenterology, Surveillance and Microbiome**

Room
Aquarius

Chairs: *Elizabeth Half (Israel)*
Peter Bauerfeind (Switzerland)
Martina Cavestro (Italy)

15' + 5' **The role of genotoxic gut bacteria in hereditary and sporadic colorectal cancer**
Dan Buchanan (Australia)

6' + 2' **Perceptions and Attitudes towards Faecal Immunochemical Testing (FIT) as a Provisional Modality for Risk-Stratified Colonoscopy in a Lynch syndrome Patient Population**
Kevin Monahan (UK)

6' + 2' **The optimal endoscopic surveillance in hereditary diffuse type gastric cancer; random or targeted biopsy taking?**
Tanya Bisseling (The Netherlands)

6' + 2' **The diagnostic yield of colonoscopic surveillance following resection of early-age onset colorectal cancer (EOCRC).**
Husam Al Maliki (UK)

6' + 2' **Four decades of endoscopic surveillance in Lynch syndrome reveals a slightly higher complication rate - a retrospective cohort study on safety and adverse events**
Alexander Frank (Sweden)

Scientific Program

Day 2 – Saturday, September 30th

6' + 2' **Efficacy and Outcomes of Pancreatic Cancer Screening Program in CAPS-Eligible versus non-CAPS-Eligible populations: A Single Center Study**
Erez Hasnis (Israel)

6' + 2' **Duodenal disease phenotype in MUTYH-associated polyposis: updated findings from an international prospective study.**
Laura Thomas (UK)

6' + 2' **The impact of a novel expert multidisciplinary meeting for the management of hereditary colorectal cancer risk**
Avani Varde (UK)

6' + 2' **Quality of Endoscopic Surveillance in Lynch Syndrome Patients at a Highly Specialized Center in Sweden - Interval, Adenoma Detection, and Cleanliness**
Sophie Walton Bernstedt (Sweden)

6' + 2' **Distinct gastric phenotype in patients with SMAD4-associated Juvenile Polyposis Syndrome: A nationwide study**
Anne Marie Jelsing (Denmark)

6' + 2' **Risk Factors and Clinical Characteristics of Young-Onset Gastric Cancer vs. Late-Onset Gastric Cancer: a case-case-study**
Marta Puzzono (Italy)

6' + 2' **Colibactin mutational signatures in NTHL1 Tumor Syndrome, MUTYH Associated Polyposis and unexplained polyposis patients**
Diantha Terlouw (The Netherlands)

6' + 2' **Characterizing unique microbiome alterations in Lynch syndrome within the druze community in Israel**
Elizabeth Half (Israel)

Scientific Program

Day 2 – Saturday, September 30th

09:00-11:00

Room
Plantaria

Group 2 – Carcinogenic mechanisms and pathways / early onset cancers / novel associations

Chairs: Richarda de Voer (The Netherlands)
Matthias Kloor (Germany)
Laura Thomas (UK)

Arsenic-free diet can decrease the risk of cancers in females from families with aggregation of breast cancers

5' + 2' Jan Lubinski (Poland)

Additive effects of selenium and arsenic can be considered for effective diagnosis of significantly lower cancer risk in brca1 carriers on arsenic free diet

5' + 2' Jan Lubinski (Poland)

Mathematical guidance for the interpretation of PCR-based MSI diagnostics

5' + 2' Alexander Zellmann (Germany)

Mathematical modeling of Lynch syndrome cancer development - A multi-scale view from the DNA over the tissue level to clinical translation

5' + 2' Saskia Haupt (Germany)

Co-evolution of mismatch repair loss and the immune response in Lynch Syndrome

8' + 2' Otilie Swinyard (UK)

The associations of circulating microRNAs and lifestyle with cancer risk among Finnish Lynch syndrome carriers

8' + 2' Tero Sievänen (Finland)

Leveraging whole exome sequencing of Lynch syndrome associated primary colorectal cancer to illuminate the aetiology of β -catenin dependent subtype.

8' + 2' Kalle Hokkanen (Finland)

Impact of Pathogenetic MMR Genotypes on Systemic Metabolomic Signatures

8' + 2' Tiina Jokela (Finland)

Scientific Program

Day 2 – Saturday, September 30th

Genome-wide DNA methylation profiles of colorectal tumors in Lynch syndrome and Familial adenomatous polyposis
Satu Makinevala (Finland)

8' + 2'

Germline NPAT pathogenic variants in hereditary nonpolyposis colorectal cancer
Mariona Terradas (Spain)

8' + 2'

MCM8 and MCM9 as germline predisposing genes for early-onset cancer, polyposis and primary ovarian insufficiency
Noah Cornelis Helderma (The Netherlands)

8' + 2'

Germline variants in PARP1 as potential cause of colonic polyposis in adults
Laura Valle (Spain)

8' + 2'

09:00-11:00

Room
Aeris

Group 3 – Families with inherited cancer/ patient organizations

Chairs: Nicola Reents (Germany)
Simone Widhalm (Germany)
Kelly Kohut (UK)

Guidelines in „plain language“ for patients affected by Lynch syndrome

8' + 3'

Katlijn Sanctorum (Belgium)

Co-design of patient information leaflets for cancer genetics

8' + 3'

Julie Young (UK)

Co-design of the Lynch Choices patient resource including cultural translation to improve equity, diversity and inclusion

8' + 3'

Kelly Kohut (UK)

The National Nursing Workshops: Adapting Delivery and Content to Increase Awareness of Lynch syndrome.

8' + 3'

Amy Sanderson (UK)

Diagnosis and management of Lynch Syndrome in an Irish Context: An Advanced Nurse Practitioner (ANP) Led Service

8' + 3'

Mechelle Loughrey (Ireland)

Scientific Program

Day 2 – Saturday, September 30th

- 8' + 3' **The United Kingdom National NHS Genomic Lynch syndrome Transformation Project: The Rise of the Genomic Practitioner**
Mandy Darbyshire (UK)
Melissa Cambell-Kelly (UK)
- 8' + 3' **The NHS English National Lynch syndrome transformation project: Setting up the Regional Lynch syndrome Expert Network for the North Thames Genomic Medicine Service Alliance (GMSA)**
Anna Koziel (UK)
- 8' + 3' **A questionnaire-based assessment of holistic clinical care for Lynch syndrome linked to regular colonoscopic surveillance episodes**
Penelope Edwards (UK)
- 8' + 3' **Identifying barriers to colonoscopic screening in asymptomatic first-degree relatives of patients with hereditary CRC in Pakistan – A pilot study.**
Raza Sayyed (Pakistan)
- 8' + 3' **Finding the missing 95%: The English National Lynch syndrome transformation project**
Kevin Monahan (UK)
- 11:00-11:30 **Coffee Break**
- 11:30-13:30 **EHTG-ESCP international Surgery Day “iSTOIC”**
See page 30-31 for details
- 11:30-13:30 **Parallel Working Groups 4-6**
- 11:30-13:30 **Group 4 – Epidemiology of hereditary cancer**
Chairs: Sigurdís Haraldsdóttir (Iceland)
Heather Hampel (USA)
Mev Dominguez (Norway)
- Room**
Aquarius
- 30' + 6' **Integrated Germline-Somatic Analysis: Research Insights from the MSK-IMPACT Initiative**
Zsofia Stadler (USA)

Scientific Program

Day 2 – Saturday, September 30th

- 9' + 3' **The rate of ATM pathogenic variants (PVs) in a series of unselected Israeli Pancreatic Cancer Patients**
Rakefet Chen-Shtoyerman (Israel)
- 9' + 3' **Colorectal cancer incidences in carriers with and without colorectal adenomas**
Pål Møller (Norway)
- 9' + 3' **Colorectal cancer incidences in path_MLH1 and path_MSH2 carriers in three continents**
Pål Møller (Norway)
- 9' + 3' **Cancer in patients with Familial adenomatous polyposis - a nationwide Danish cohort study with matched controls**
Anne Marie Jelsing (Denmark)
- 9' + 3' **Whole genome sequencing findings in families tested negative based on family history**
Mev Dominguez Valentin (Norway)
- 9' + 3' **Incidence of adenomatous polyps and colorectal cancer in Dutch patients with PMS2-associated Lynch syndrome undergoing surveillance: a prospective cohort analysis**
Katarina Andini (The Netherlands)
- 9' + 3' **Prevalence of familial pancreatic cancer and inherited cancer syndromes in pancreatic cancer patients in Iceland 2000-2021**
Ásthildur Rafnsdóttir (Iceland)



Scientific Program

Day 2 – Saturday, September 30th

11:30-13:30

Room
Plantaria

Group 5 – BY INVITATION ONLY:

Brainstorming on the harmonization of global Lynch syndrome guidelines and initiation of the process. Step one: identification of the discrepancy-based questions to be addressed

*Chairs: Giulia Cavestro (Italy)
Alessandro Mannucci (Italy)
Gabriela Möslein, Germany*

We are planning a harmonization of the global guidance for Lynch syndrome.

The topic is the initiative to harmonize the different evidence-based guidelines for Lynch syndrome and elaborate a global consented guideline based on the newest available literature and – of course – expert guidance via a Delphi process for questions without sufficient evidence. As you may be aware, EHTG has published previously a sequence of guidelines for Lynch syndrome (LS), first based on expert opinion only and in 2021, after an extensive process of literature review and Delphi consensus the first “dynamic” guideline for LS in BJS (T. T. Seppälä et al., European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender, British Journal of Surgery, Volume 108, Issue 5, May 2021, Pages 484–498, <https://doi.org/10.1002/bjs.11902>)

We have invited global experts in order to discuss and initiate the process.

Invited individuals will receive the link beforehand.



Scientific Program

Day 2 – Saturday, September 30th

11:30-13:15

Room
Aeris

Group 6 – Personalized medicine and targeted prevention

*Chairs: Anja Wagner (The Netherlands)
Nadir Arber (Israel)
Frank A. Sinicrope (USA)*

Beyond Checkpoint Blockade for dMMR/MSI-High Cancers - Advances and Challenges
Kai-Keen Shiu (UK)

20' + 10'

A significant proportion of advanced colonic neoplasia could have been missed, if we had adopted the recommendation to raise the age to start colonoscopy to 35 for subjects with path_MSH6 mutation
Zohar Levi (Israel)

10' + 5'

Detection of microsatellite instability using plasma-derived extracellular vesicle DNA – a new perspective for tumor surveillance in Lynch syndrome?
Lena Bohaumilitzky (Germany)

10' + 5'

Comprehensive molecular profiling of patient-derived tumor organoids uncovers in vitro drug sensitivities of sporadic and hereditary colorectal cancers
Erdogan Pekcan Erkan (Finland)

10' + 5'

Clinical Use Scenarios of Breast Cancer Polygenic Risk Score in Women
Peeter Padrik (Estonia)

10' + 5'

Nous-209 genetic vaccine encoding shared cancer neoantigens has demonstrated safety and robust immunogenicity in patients with Microsatellite Instable Tumors and is under evaluation in Lynch syndrome carriers
Elisa Scarselli (Italy)

10' + 5'

13:30-14:30

Lunch

14:30-16:30

EHTG-ESCP international Surgery Day “iSTOIC”
See page 30-31 for details

Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30 Parallel Working Groups 7-9

14:30-16:30 **Group 7 – Genetic Counselling & Management (incl. Lab diagnosis, NA seq, MMR variant interpretation)**

Room
Aquarius

Section 1: Lynch syndrome - national strategies and registries

Chair: *Fiona Lalloo (UK)*

The UK-model

Laura Monje-Garcia (UK)

15'

The DK-model

Christina Therkildsen (Denmark)

15'

Section 2: Ethical dilemmas – Risk information in families

Chair: *Kaisa Fritzell (Sweden)*

Experiences from direct provider-mediated cascade-testing in Lynch syndrome families – the Danish model

Lars Lindberg (Denmark)

8'

Mismatch repair deficiency – extent of investigation and management of “unexplained” cases: UK cancer genetics group national consensus meeting

Terri McVeigh (UK)

8'

Lynch syndrome Super-spreader: Legal, ethical, regulatory and social implications of sperm donors' genetic screening

Zohar Levi (Israel)

8'

Section 3: Diagnostic tools – dilemmas

Chair: *Inge Bernstein (Denmark)*

MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with Lynch syndrome

Maartje Nielsen (The Netherlands)

8'

Scientific Program

Day 2 – Saturday, September 30th

An Exploration of the Somatic and Germline Mutational Profiles of Early-Onset Colorectal Cancer Based on Two UK Patient Cohorts
Penelope Edwards (UK)

8'

Challenging interpretation of germline TP53 variants

Henriett Butz (Hungary)

8'

Section 4: Posters – Two minutes pitch + 1 slide

Chair: *Inge Bernstein (Denmark)*

Prevalence of CHEK2-Pathogenic/Likely Pathogenic Variant - Positive and Management in Hereditary Breast Cancer Syndrome in Our Centre.

Francisco Javier Jiménez-Ruiz (Spain)

2'

Development and performance of a PMS2-specific NGS product for genetic testing of Lynch syndrome

Jessica De Loma Olson (Sweden)

2'

Enhancing interpretation and classification of POLEand POLD1 variants: Gene-specific recommendations and in vitro functional study system development

Julen Viana (Spain)

2'

RNA-based analyses expand the molecular genetic diagnostic workflow of Lynch syndrome

Vince Kornél Grolmusz (Hungary)

2'

The landscape of Lynch syndrome in the Israeli population

Zohar Levi (Israel)

2'

Summary and Discussion

Fiona Lalloo (UK)

22'

Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30

Room
Plantaria

Group 8 – Gynaecological, urology and other extra-intestinal cancers

Chairs: *Emma Crosbie (UK)*
Maria Rasmussen (Denmark)
John Burn (UK)

Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors

Maria Rasmussen (Denmark)

8' + 2'

ONLY AS
VIRTUAL
POSTER

Lynch syndrome: Does Hormonal Contraception Protect Against Endometrial Cancer?

Marie Mawet (France)

Highly sensitive microsatellite instability assessment in minimally invasive gynaecological samples allows detection of mismatch repair-deficient endometrial cancer

Julia Canet (Spain)

8' + 2'

A pilot study using the Newcastle MSI-Plus assay as a “urine liquid biopsy” in patients with upper tract urothelial cancers and in asymptomatic MSH2 Lynch syndrome carriers.

Rebecca Hall (UK)

8' + 2'

Outcomes of Lynch syndrome endometrial cancer surveillance in a nation-wide cohort

Anja Wagner (The Netherlands)

8' + 2'

MSI detection of MMR deficient endometrial tumours is influenced by assay sensitivity and MMR gene affected

Michael Jackson (UK)

8' + 2'

Breast magnetic resonance screening for BRCA and non-BRCA pathogenic variant carriers

Mev Dominguez Valentin (Norway)

8' + 2'

Home-based urine sampling for endometrial cancer detection in Lynch syndrome

Jean-Ellen Johnson (UK)

8' + 2'

A Mismatch in Guidelines for Lynch syndrome: A Systematic Review & Meta-Analysis

Neil Ryan (UK)

8' + 2'

Scientific Program

Day 2 – Saturday, September 30th

14:30-16:30

Room
Aeris

Group 9 – Immunology and Pathology

Chairs: *Shizuko Sei (USA)*
Vinaya Gunasri (UK)
Aysel Ahadova (Germany)

CAPIT Center for LNP RNA Cancer Immunoprevention

Steve Lipkin (USA)

30'

Relationship between neoantigen load and the T cell response in mismatch-repair deficient / ultramutated POLE-mutant cancers

David Church (UK)

30'

The immune profile of Lynch syndrome-associated colorectal adenomas pinpoints the main determinants of immune activation

Lena Bohaumilitzky (Germany)

9'

Immune evasion is more frequent among prevalent than incident Lynch syndrome colorectal cancers

Aysel Ahadova (Germany)

9'

HLA Type as a possible modulator of cancer risk in Lynch syndrome: first data from the INDICATE Network

Aysel Ahadova (Germany)

9'

Math4INDICATE - Methodological challenges for investigating the influence of the HLA genotype on cancer risk in Lynch syndrome

Saskia Haupt (Germany)

9'

Tumor3D – A platform for virtual 3D tumor models from histology sections

Alexander Zeilmann (Germany)

9'

Discussion

15'

16:30-17:00

Coffee Break

Scientific Program

Day 2 – Saturday, September 30th

17:00-18:45

Room
Humanitas

CMMRD Session

*Chairs: Crystelle Colas (France)
Katharina Wimmer (Austria)*

CMMRD: the clinical spectrum and differential diagnoses

15' *Katharina Wimmer (Austria)*

New guidelines for CMMRD diagnosis, counseling, surveillance, clinical management and quality of life

15' *Crystelle Colas (France)*

Gastroenterological surveillance for CMMRD

15' *Mariëtte van Kouwen (The Netherlands)*

Place of immune checkpoint therapy in CMMRD

15' *Léa Guerrini-Rousseau (France)*

Neuroimaging features of CMMRD syndrome and comparison of brain MRIs of children with high-grade gliomas according to MMR gene mutational status

15' *Volodia Dangouloff-Ros (France)*

Update about systemic immunological implications of CMMRD

15' *Matthias Kloor (Germany)*

18:30-18:45

CMMRD Speed Talks

A validated highly sensitive microsatellite instability assay accurately identifies biallelic germline PMS2 mutation carriers among Constitutional Mismatch Repair Deficiency individuals.

5' *Marta Pineda (Spain)*

Cases of constitutional mismatch repair deficiency mimicking Lynch syndrome caused by hypomorphic variants

5' *Richard Gallon (UK)*

Digestive burden of patients with Constitutional MisMatch Repair Deficiency syndrome, diagnostic pitfalls and experience of immunotherapy: a report from the C4CMMRD database.

5' *Chrystelle Colas (France)*


Scientific Program

Day 2 – Saturday, September 30th

19:30 +

Conference Dinner

Conference Dinner at La Bohème



The Restaurant La Bohème is situated in the Old Town of Vilnius, about 10-15 minutes walking distance from the Panorama Hotel

Šv. Ignoto g. 4/3 01120 Vilnius
www.laboHEME.lt





EHTG-ESCP international Surgery Day “iSTOIC”*

Room
Humanitas

Day 2 – Saturday, September 30th

09:00-11:00	IPAA Technical Considerations I <i>Chairs: Valerio Celentano (UK) Dieter Hahnloser (Switzerland)</i>
09:00-09:20	Staging, timing and technical details of IPAA in FAP <i>Feza Remzi (USA)</i>
09:20-9:40	What is different for UC-Pouches and FAP-pouches? <i>Janindra Warsusavitarné (UK)</i>
09:40-10:00	Plenary Discussion
10:00-10:20	Stoma yes or no for FAP pouches – virtual ileostomy, early stoma closure? <i>Valerio Celentano (UK)</i>
10:20-10:40	Appraisal of robotic IPAA – equal or better? <i>Marcos Gomez Ruiz (Spain)</i>
10:40-11:00	Plenary Discussion
11:00-11:30	Coffee Break
11:30-13:30	Surgery and Genetics <i>Chairs: John Burn (UK) Neil Smart (UK)</i>
11:30-11:50	Crash Course for Surgeons: What you always wanted to know and never dared to ask about hereditary cancer <i>Heather Hampel (USA)</i>
11:50-12:10	Collaborative Networks & advancing genomics knowledge for Surgeons <i>Frank McDermott (UK)</i>
12:10-12:30	Implementing a nurse led mainstreaming pathway for Lynch syndrome <i>Emma Jenkins (UK)</i>

* International Surgical Group of Those Operating on Inherited colorectal Cancer

EHTG-ESCP international Surgery Day “iSTOIC”*

Room
Humanitas

Day 2 – Saturday, September 30th

12:30-13:30	Plenary discussion
13:30-14:30	Lunch Break
14:30-16:30	IPAA Technical Considerations II <i>Chairs: Narimantas Samalavičius (Lithuania) Feza Remzi (USA)</i>
14:30-14:50	Is there still a place for hand-assisted IPAA? Worth learning? <i>Narimantas Samalavičius (Lithuania)</i>
14:50-15:10	Pouch failure: taTME redo pouch <i>Antonio Lacy (Spain)</i>
15:10-15:30	Pouch failure: is continent ileostomy an alternative? <i>Gabriela Möslein (Germany)</i>
15:30-15:45	FAP and Desmoids <i>Matt Kalady (USA)</i>
15:45-16:00	FAP and Endometriosis – is it an issue? <i>Hermann Kessler (USA)</i>
16:00-16:30	Plenary Discussion



European Hereditary
Tumour Group

Scientific Program

Room
Humanitas

Day 3 – Sunday, October 1st

08:00-09:00 EHTG Business Meeting

09:00-10:00 **WG Reporting Back Session and Collaborative Studies**

*Chairs: Laura Valle (Spain)
Rolf Sijmons (The Netherlands)
Ottilie Swinyard (UK)*

10:00-10:30 **Coffee Break**

10:30-11:30 **Hot Topics**

*Chairs: Lone Sunde (Denmark)
Alessandro Manucci (Italy)
Lior Katz (Israel)*

10'+5' **Colonoscopy interval in Lynch syndrome: Time to start a clinical trial?**

Martina Cavestro (Italy)

10'+5' **FIT for surveillance in Lynch syndrome**

Kevin Monahan (UK)

10'+5' **Comprehensive Analysis of Germine Drivers in Endometrial Cancer**

Ying Liu (USA)

10'+5' **Confident to mainstream genomic testing in Lynch syndrome?**

A competency guide for nurses.

Siobhan John (UK)

11:30-12:30 **Networking with patients representatives and organizations**

*Chairs: Kelly Kohut (UK)
Simone Widhalm (Germany)
Nicole Reents (Germany)*

- Patient presentations about their life experiences
- Priorities for research topics
- Gaps in clinical care and patient resources
- Psychosocial aspect for hereditary cancer patients

20'+10' 12:30-13:00 **Pathology and clinical data in childhood in FAP, MAP, JPS, PHTS**

*Chairs: Katharina Wimmer (Austria)
Marion Dhooge (France)*

Speaker: Andrew Latchford (UK)

Scientific Program

Room
Humanitas

Day 3 – Sunday, October 1st

13:00-13:30 **Lunch**

13:30-14:00 **Late breaking abstracts session**

*Chairs: Pål Møller (Norway)
Henriett Butz (Hungary)*

8'+2' **Late abstract 1**

Colorectal carcinomas from path_MSH6 carriers display a lower level of microsatellite instability and evoke weaker immune responses

Noah Cornelis Helderma (The Netherlands)

8'+2' **Late abstract 2**

Re-classification of two MLH1 variants of uncertain significance using clinical data and functional assays

Jane Hübertz Frederiksen (Denmark)

8'+2' **Late abstract 3**

The Benefit of Pancreatic Cancer Surveillance in Carriers of Germline BRCA1/2 Pathogenic Variants

Ido Laish (Israel)

14:00-14:45 **Newly emerging technologies**

*Chairs: Zsofia Stadler (USA)
Ellis Eikenboom (The Netherlands)
Marta Pineda (Spain)*

10'+5' **Liquid biopsy in CRC for early detection and therapy monitoring based on whole genome sequencing data**

Ariane Hallermayr (Germany)

10'+5' **MMR functional analysis in diagnostics: the INVUSE project**

Tjakko J. van Ham (The Netherlands)

10'+5' **Implementing RAMAN spectroscopy in screening for Lynch patients**

Dean Harris (UK)

14:45-15:00 **Farewell**

Faculty

Ahadova, Aysel <i>p. 10, 27</i>	Heidelberg University Hospital Heidelberg, Germany
Al Maliki, Husam <i>p. 16</i>	Sussex Medical School Brighton, United Kingdom
Andini, Katarina <i>p. 21</i>	UMCG - University Medical Centre Groningen Groningen, The Netherlands
Arber, Nadir <i>p. 23</i>	Sourasky Medical Center Tel-Aviv, Israel
Backman, Ann-Sofie <i>p. 10</i>	Karolinska University Hospital Stockholm, Sweden
Bajwa-ten Broeke, Sanne <i>p. 10</i>	UMCG - University Medical Centre Groningen Groningen, The Netherlands
Bauerfeind, Peter <i>p. 16</i>	Hirslanden Clinic St. Anna Zürich, Switzerland
Bernstein, Inge <i>p. 24, 25</i>	Aalborg University Hospital Aalborg, Denmark
Bisseling, Tanya <i>p. 11, 13, 16</i>	Radboud University Medical Center Nijmegen, The Netherlands
Bohauimilitzky, Lena <i>p. 10, 12, 23</i>	Heidelberg University Hospital Heidelberg, Germany
Buchanan, Dan <i>p. 16</i>	University of Melbourne Melbourne, Australia
Burn, John <i>p. 26, 30</i>	Newcastle University Newcastle upon Tyne, United Kingdom
Butz, Henriett <i>p. 25, 33</i>	National Institute of Oncology Department of Molecular Genetics Budapest, Hungary
Cambell-Kelly, Melissa <i>p. 20</i>	Norfolk and Norwich University Hospitals NHS Foundation Trust Norwich, United Kingdom
Canet-Hermida, Julia <i>p. 26</i>	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Capella, Gabriel <i>p. 12</i>	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain

Faculty

Cavestro, Martina <i>p. 11, 16, 22, 32</i>	IRCCS San Raffaele Scientific Institute Milan, Italy
Celentano, Valerio <i>p. 30</i>	Chelsea and Westminster Hospital NHS Foundation Trust London, United Kingdom
Chen-Shtoyerman, Rakefet <i>p. 21</i>	Ariel University Ariel, Israel
Church, David <i>p. 23</i>	University of Oxford Oxford, United Kingdom
Colas, Crystelle <i>p. 28</i>	Institut Curie Paris, France
Crosbie, Emma <i>p. 22, 26</i>	Manchester University NHS Foundation Trust Manchester, United Kingdom
Dangouloff-Ros, Volodia <i>p. 28</i>	Necker University Hospital Paris, France
Darbyshire, Mandy <i>p. 20</i>	Manchester University NHS Foundation Trust Manchester, United Kingdom
De Loma Olson, Jessica <i>p. 25</i>	Devyser AB Hägersten, Sweden
de Voer, Richarda <i>p. 18</i>	Radboud University Medical Center Nijmegen, The Netherlands
Dhooge, Marion <i>p. 32</i>	Hopital Cochin Paris, France
Diez de los Tios, Celia <i>p. 14</i>	University of Navarra Madrid, Spain
Dominguez Valentin, Mev <i>p. 12, 15, 20, 21, 26</i>	Oslo University Hospital Oslo, Norway
Edwards, Penelope <i>p. 13, 20, 25</i>	St. Marks Hospital London, United Kingdom
Eikenboom, Ellis <i>p. 11, 33</i>	Erasmus MC Cancer Institute Rotterdam, The Netherlands
Erkan, Pekcan <i>p. 12, 23</i>	Tampere University and TAYS Cancer Centre Tampere, Finland
Frank, Alexander <i>p. 16</i>	Karolinska University Hospital Stockholm, Sweden

Faculty

Fritzell, Kaisa <i>p. 24</i>	Karolinska University Hospital Stockholm, Sweden
Fruscio, Robert <i>p. 11</i>	Università degli Studi di Milano-Bicocca Milan, Italy
Gallon, Richard <i>p. 11, 28</i>	Newcastle University Newcastle upon Tyne United Kingdom
Georgiou, Demetra <i>p. 10</i>	Imperial and North West London Healthcare London, United Kingdom
Goldberg, Yael <i>p. 11</i>	Rabin Medical Center Petach Tikva, Israel
Gomez Ruiz, Marcos <i>p. 30</i>	Hospital Universitario Marques de Valdecilla Santander, Spain
Grolmusz, Vince Kornél <i>p. 25</i>	National Institute of Oncology Budapest, Hungary
Guerrini-Rousseau, Léa <i>p. 28</i>	Université Paris-Saclay Villejuif, France
Gunasri, Vinaya <i>p. 27</i>	University College London London, United Kingdom
Hahnloser, Dieter <i>p. 30</i>	Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland
Half, Elizabeth <i>p. 11, 17</i>	Rambam Health Care Campus Haifa, Israel
Hall, Rebecca <i>p. 26</i>	Newcastle University Newcastle upon Tyne United Kingdom
Hallermayr, Ariane <i>p. 33</i>	MGZ Medical Center of Genetics Munich, Germany
Hampel, Heather <i>p. 11, 20, 30</i>	Ohio State University Columbus OH, USA
Haraldsdottir, Sigurdís <i>p. 20</i>	Landspítali University Hospital Reykjavík, Iceland
Harris, Dean <i>p. 33</i>	Swansea University Swansea, United Kingdom
Hasnis, Erez <i>p. 17</i>	Rambam Health Care Campus Haifa, Israel

Faculty

Haupt, Saskia <i>p. 18, 27</i>	Heidelberg University and Heidelberg Institute for Theoretical Studies (HITS) Heidelberg, Germany
Helderman, Noah Cornelis <i>p. 19, 33</i>	LUMC Leiden University Medical Center Leiden, The Netherlands
Hodan, Rachel <i>p. 11</i>	Stanford University Palo Alto, USA
Hokkanen, Kalle <i>p. 18</i>	Tampere University and TAYS Cancer Centre Tampere, Finland
Hübertz-Frederiksen, Jane <i>p. 12, 33</i>	Copenhagen University Hospital, Copenhagen, Denmark
Jackson, Michael <i>p. 26</i>	Newcastle University Newcastle upon Tyne United Kingdom
Jelsig, Anne Marie <i>p. 12, 21, 19</i>	Rigshospitalet Copenhagen, Denmark
Jenkins, Emma <i>p. 30</i>	South Devon Healthcare NHS Foundation Trust Torquai, United Kingdom
Jiménez-Ruiz, Francisco Javier <i>p. 25</i>	Hospital Universitario Juan Ramón Jiménez Huelva, Spain
John, Siobhan <i>p. 32</i>	Royal United Hospital Bath, United Kingdom
Johnson, Jean-Ellen <i>p. 26</i>	Manchester University NHS Foundation Trust Manchester, United Kingdom
Jokela, Tiina <i>p. 13, 18</i>	University of Jyväskylä Jyväskylä, Finland
Kalady, Matt <i>p. 31</i>	Ohio State University Columbus OH, USA
Katz, Lior <i>p. 32</i>	Hadassah Medical Center Jerusalem, Israel
Kessler, Hermann <i>p. 31</i>	Cleveland Clinic Cleveland, Ohio, USA
Kloor, Matthias <i>p. 10, 18, 28</i>	Heidelberg University Hospital Heidelberg, Germany

Faculty

Kohut, Kelly <i>p. 10, 19, 32</i>	St George's University Hospitals NHS Foundation Trust London, United Kingdom
Koziel, Anna <i>p. 20</i>	London North West University Healthcare NHS Trust London, United Kingdom
Lacy, Antonio <i>p. 31</i>	Clinica Rotger Barcelona, Spain
Laish, Ido <i>p. 33</i>	Sheba Medical Center Ramat Gan, Israel
Laloo, Fiona <i>p. 24, 25</i>	Manchester Centre for Genomic Medicine Manchester, United Kingdom
Latchford, Andrew R. <i>p. 32</i>	St. Marks Hospital London, United Kingdom
Levi, Zohar <i>p. 10, 23, 24, 25</i>	Rabin Medical Center Petach Tikva, Israel
Lindberg, Lars <i>p. 12, 24</i>	Copenhagen University Hospital Hvidovre, Denmark
Lipkin, Steve <i>p. 23</i>	Weill Cornell Medicine New York, USA
Liu, Ying <i>p. 32</i>	Memorial Sloan Kettering Cancer Center New York, USA
Loughrey, Mechelle <i>p. 14, 19</i>	St. Vincent's University Hospital Dublin, Ireland
Lubinski, Jan <i>p. 18</i>	Pomeranian Medical University Szczecin, Poland
Mäki-Nevala, Satu <i>p. 19</i>	University of Helsinki Helsinki, Finland
Manucci, Alessandro <i>p. 22, 32</i>	San Raffaele Hospital Milan, Italy
Mawet, Marie <i>p. 26</i>	Hopital Tenon Paris, France
McDermott, Frank <i>p. 30</i>	Royal Devon University Healthcare Trust Exeter, Ireland
McVeigh, Terri <i>p. 24</i>	Royal Marsden NHS Foundation Trust London, United Kingdom

Faculty

Moeslein, Gabriela <i>p. 10, 22, 31</i>	Evangelic Bethesda Hospital Duisburg, Germany
Møller, Pål <i>p. 15, 21, 33</i>	The Norwegian Radium Hospital Oslo, Norway
Monahan, Kevin <i>p. 16, 20, 32</i>	St. Marks Hospital London, United Kingdom
Monje-Garcia, Laura <i>p. 14, 24</i>	London North West University Healthcare NHS Trust London, United Kingdom
Moschini, Marco <i>p. 11</i>	San Raffaele Hospital Milan, Italy
Nielsen, Maartje <i>p. 24</i>	LUMC Leiden University Medical Centre Leiden, The Netherlands
Nordstroem, Ulla <i>p. 11</i>	Rigshospitalet Copenhagen, Denmark
Padrik, Peeter <i>p. 23</i>	Tartu University Hospital Tartu, Estonia
Pellino, Gianluca <i>p. 30</i>	Università degli Studi dalla Campania „Luigi Vanvitelli“ Naples, Italy
Pineda, Marta <i>p. 33</i>	Catalan Institute of Oncology (IDIBELL) Hospitalet de Llobregat, Spain
Puzzono, Marta <i>p. 17</i>	San Raffaele Hospital Milan, Italy
Rafnsdóttir, Ásthildur <i>p. 21</i>	Landspítali University Hospital Reykjavik, Iceland
Rasmussen, Maria <i>p. 26</i>	Copenhagen University Hospital Hvidovre, Denmark
Reents, Nicole <i>p. 19, 32</i>	SemiColon Germany Mönchengladbach, Germany
Remzi, Feza <i>p. 30, 31</i>	NYU Langone Inflammatory Bowel Disease Center New York, USA
Ryan, Neil <i>p. 11, 15, 26</i>	University of Edinburgh Edinburgh, United Kingdom
Samalavicius, Narimantas <i>p. 31</i>	Klaipeda University Hospital Klaipeda, Lithuania



Faculty

Sanctorum, Katlijn
p. 12, 19

Sanderson, Amy
p. 19

Sayyed, Raza
p. 20

Scarselli, Elisa
p. 23

Sei, Shizuko
p. 10, 27

Shiu, Kai-Keen
p. 23

Sievänen, Tero
p. 18

Sijmons, Rolf
p. 32

Sinicrope, Frank A.
p. 10, 23

Smart, Neil
p. 30

Stadler, Zsafia
p. 20, 33

Sunde, Lone
p. 32

Swinyard, Otilie
p. 10, 18, 32

Terlouw, Diantha
p. 13, 17

Terradas, Mariona
p. 19

Therkildsen, Christina
p. 24

Thomas, Laura
p. 17, 18

FAPA
Brussels, Belgium

Sheffield Teaching Hospitals
Sheffield, United Kingdom

Patel Hospital
Karachi, Pakistan

Nouscom Srl
Rome, Italy

National Cancer Institute
Maryland, USA

UCL Cancer Institute
London, United Kingdom

University of Jyväskylä
Jyväskylä, Finland

University Medical Centre
Groningen
Groningen, The Netherlands

Mayo Clinic
Rochester, USA

Royal Devon & Exeter Hospital
Exeter, United Kingdom

Memorial Sloan Kettering
Cancer Center
New York, USA

Aalborg University Hospital
Aalborg, Denmark

Barts Cancer Institute
London, United Kingdom

LUMC Leiden University
Medical Centre
Leiden, The Netherlands

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

Copenhagen University Hospital
Hvidovre, Denmark

Swansea University
Swansea, United Kingdom

Faculty

Valle, Laura
p. 12, 19, 32

van Ham, Tjakko
p. 33

van Enckevort, Esther
p. 11

van Kouwen, Mariëtte
p. 28

Varde, Avani
p. 17

Viana-Errasti, Julen
p. 24

Wagner, Anja
p. 11, 12, 26

Walton Bernstedt, Sophie
p. 17

Warsusavitarne, Janindra
p. 30

Widhalm, Simone
p. 19, 32

Wimmer, Katharina
p. 28, 32

Young, Julie
p. 19

Zaffaroni, Gloria
p. 11

Zeilmann, Alexander
p. 18, 27

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

Erasmus MC Cancer Institute
Rotterdam, The Netherlands

UMCG
Houten, The Netherlands

Radboud University Medical Center
Nijmegen, The Netherlands

Imperial College London
London, United Kingdom

Catalan Institute of Oncology
(IDIBELL)
Hospitalet de Llobregat, Spain

Erasmus MC Cancer Institute
Rotterdam, The Netherlands

Karolinska University Hospital
Stockholm, Sweden

St. Marks Hospital
London, United Kingdom

Semi-Colon
Düsseldorf, Germany

Medical University of Innsbruck
Innsbruck, Austria

Patient representative
Southampton, United Kingdom

Evangelic Bethesda Hospital
Duisburg, Germany/Italy

Heidelberg University and
Heidelberg Institute for Theoretical
Studies (HITS)
Heidelberg, Germany





Vilnius in the evening ©Laimonas Ciūnys_Lithuania Travel

Supported by



7TH ANNUAL MEETING
Vilnius • 2023